These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 34799647)

  • 21. Serum B cell-activating factor (BAFF) level in connective tissue disease associated interstitial lung disease.
    Hamada T; Samukawa T; Kumamoto T; Hatanaka K; Tsukuya G; Yamamoto M; Machida K; Watanabe M; Mizuno K; Higashimoto I; Inoue Y; Inoue H
    BMC Pulm Med; 2015 Sep; 15():110. PubMed ID: 26424433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.
    Cao XY; Hu SS; Xu D; Li MT; Wang Q; Hou Y; Zeng XF
    Int J Rheum Dis; 2019 Jan; 22(1):108-115. PubMed ID: 30592376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients.
    Hu Y; Wang LS; Jin YP; Du SS; Du YK; He X; Weng D; Zhou Y; Li QH; Shen L; Zhang F; Su YL; Sun XL; Ding JJ; Zhang WH; Cai HR; Dai HP; Dai JH; Li HP
    Clin Respir J; 2017 May; 11(3):337-345. PubMed ID: 26077281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum YKL-40 and Serum Krebs von den Lungen-6 as Potential Predictive Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease.
    Liang B; Zhang Y; Ke D; Yan R; Jiang MN; Li L; Zhang LX; Zhao XG; Yuan GP; Xu B; Liu XM
    Immunol Invest; 2024 Aug; 53(6):989-1000. PubMed ID: 38900045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.
    Lee JS; Lee EY; Ha YJ; Kang EH; Lee YJ; Song YW
    Arthritis Res Ther; 2019 Feb; 21(1):58. PubMed ID: 30764869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y; Fu Q; Wang R; Guo Q; Bao C
    J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease.
    Qin H; Xu XP; Zou J; Zhao XJ; Wu HW; Zha QF; Chen S; Kang Y; Jiang HD
    Pulmonology; 2019; 25(3):143-148. PubMed ID: 30007895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
    Xue M; Guo Z; Cai C; Sun B; Wang H
    Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seasonal variation of serum KL-6 concentrations is greater in patients with hypersensitivity pneumonitis.
    Ohnishi H; Miyamoto S; Kawase S; Kubota T; Yokoyama A
    BMC Pulm Med; 2014 Aug; 14():129. PubMed ID: 25098177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Panel of serum biomarkers for differential diagnosis of idiopathic interstitial lung disease and interstitial lung disease-secondary to systemic autoimmune rheumatic disease.
    d'Alessandro M; Cameli P; Cotton CV; Lamb JA; Bergantini L; Gangi S; Sugden S; Spencer LG; Frediani B; New RP; Chinoy H; Bargagli E; Conticini E
    PLoS One; 2024; 19(10):e0311357. PubMed ID: 39361584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositis.
    Johnson C; Rosen P; Lloyd T; Horton M; Christopher-Stine L; Oddis CV; Mammen AL; Danoff SK
    Respir Med; 2017 Sep; 130():52-54. PubMed ID: 29206633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review.
    d'Alessandro M; Bergantini L; Cameli P; Vietri L; Lanzarone N; Alonzi V; Pieroni M; M Refini R; Sestini P; Bonella F; Bargagli E
    Biomark Med; 2020 Jun; 14(8):665-674. PubMed ID: 32613855
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases: A meta-analysis.
    Zhong D; Wu C; Bai J; Hu C; Xu D; Wang Q; Zeng X
    Medicine (Baltimore); 2020 Apr; 99(16):e19695. PubMed ID: 32311947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression.
    Stock CJW; Hoyles RK; Daccord C; Kokosi M; Visca D; De Lauretis A; Alfieri V; Kouranos V; Margaritopoulos G; George PM; Molyneaux PL; Chua F; Maher TM; Abraham DJ; Ong V; Donovan J; Sestini P; Denton CP; Wells AU; Renzoni EA
    Respirology; 2021 May; 26(5):461-468. PubMed ID: 33336433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis.
    Hamai K; Iwamoto H; Ishikawa N; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Ohshimo S; Fujitaka K; Hamada H; Hattori N; Kohno N
    Dis Markers; 2016; 2016():4759040. PubMed ID: 27293304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seasonal fluctuation of serum Krebs von den Lungen-6 levels in systemic sclerosis-associated interstitial lung disease.
    Hirose H; Higuchi T; Takagi K; Tochimoto A; Ichimura Y; Harigai M; Kawaguchi Y
    Int J Rheum Dis; 2024 Jul; 27(7):e15254. PubMed ID: 38973340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases].
    Zhu C; Zhao YB; Kong LF; Li ZH; Kang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2016 Feb; 39(2):93-7. PubMed ID: 26879611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive biomarker analysis of patients with idiopathic pulmonary fibrosis and interstitial lung disease with healthy individuals.
    Balci A; Düz ME; Vurmaz A; Çilekar Ş; Kaya F
    Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5468-5479. PubMed ID: 37401283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The diagnostic value of serum KL-6 in connective tissue disease associated interstitial lung disease].
    Wu X; Wu LJ; Luo CN; Shi YM; Zou JM; Meng XY
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3172-3175. PubMed ID: 31694110
    [No Abstract]   [Full Text] [Related]  

  • 40. Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases.
    Bergantini L; d'Alessandro M; Vietri L; Rana GD; Cameli P; Acerra S; Sestini P; Bargagli E
    Immunol Res; 2020 Dec; 68(6):414-421. PubMed ID: 33089426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.